US20020110812A1 - Nucleic acid collection barrier method and apparatus - Google Patents
Nucleic acid collection barrier method and apparatus Download PDFInfo
- Publication number
- US20020110812A1 US20020110812A1 US09/781,873 US78187301A US2002110812A1 US 20020110812 A1 US20020110812 A1 US 20020110812A1 US 78187301 A US78187301 A US 78187301A US 2002110812 A1 US2002110812 A1 US 2002110812A1
- Authority
- US
- United States
- Prior art keywords
- reagents
- specimen
- nucleic acid
- barrier
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 72
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 72
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 72
- 230000004888 barrier function Effects 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 89
- 238000004458 analytical method Methods 0.000 claims abstract description 32
- 239000008280 blood Substances 0.000 claims abstract description 21
- 238000002844 melting Methods 0.000 claims abstract description 14
- 230000008018 melting Effects 0.000 claims abstract description 14
- 230000001105 regulatory effect Effects 0.000 claims abstract 4
- 238000000605 extraction Methods 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 230000002934 lysing effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 239000001226 triphosphate Substances 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- -1 nucleoside triphosphate Chemical class 0.000 claims description 2
- 238000000184 acid digestion Methods 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 20
- 210000004209 hair Anatomy 0.000 abstract description 16
- 238000011109 contamination Methods 0.000 abstract description 11
- 238000012545 processing Methods 0.000 abstract description 8
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 210000004379 membrane Anatomy 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000003860 storage Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005382 thermal cycling Methods 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 231100000640 hair analysis Toxicity 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012807 PCR reagent Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZKKBWNOSVZIFNJ-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;diphosphono hydrogen phosphate Chemical compound O=C1NC(N)=NC2=C1NC=N2.OP(O)(=O)OP(O)(=O)OP(O)(O)=O ZKKBWNOSVZIFNJ-UHFFFAOYSA-N 0.000 description 1
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VQRWLYMKQQBDFK-UHFFFAOYSA-N diphosphono hydrogen phosphate;5-methyl-1h-pyrimidine-2,4-dione Chemical compound CC1=CNC(=O)NC1=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O VQRWLYMKQQBDFK-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- This invention relates to a method and apparatus to temporally regulate analysis of a nucleic acid.
- the collected samples are routinely stored in various containers. After collection of the specimen, such as blood or hair, the container is usually sealed to isolate the specimen from the environment until analysis is performed. If analysis is postponed or if off-site analysis is to be performed, some samples may be maintained in a controlled environment in order to sustain specimen integrity. Further, the container must be rugged enough to withstand transit and storage without compromising the specimen. For example, samples collected at crime scenes must be accurately identified and described, and transported to a lab for subsequent analysis.
- sample contamination is a concern since, as the specimen is processed, the sample is manipulated with the risk of identification error and/or sample contamination from exogenous nucleic acid, as nucleic acids are ubiquitous and contamination may occur from innocuous sources such as dust.
- environmental contamination may be a concern, since a blood sample could contaminate the surrounding environment.
- the container or specimen could be potentially misidentified or misplaced with each handling step, resulting in incorrect or incomplete sample identification.
- Biological samples often are subjected to nucleic acid analysis to identify the source of the sample, or to identify one or more features of a sample.
- a standard analytical tool for nucleic acid analysis of specimens is the polymerase chain reaction (PCR). The basis of PCR is that it exponentially multiplies the quantity of nucleic acid extracted from a specimen to generate a quantity sufficient for analysis.
- PCR requires multiple reagents appropriate for amplification, such as a buffer, all four deoxyribonucleoside triphosphates (dNTP) (i.e., adenine triphosphate or dATP, thymine triphosphate or dTTP, cytosine triphosphate or dCTP, and guanine triphosphate or dGTP), magnesium, a polynucleotide polymerase enzyme, and at least one oligonucleotide primer.
- dNTP deoxyribonucleoside triphosphates
- nucleic acid is extracted from a specimen and added to the above reagents.
- the nucleic acid is denatured at a temperature between 90° C. and 100° C. to create two single-stranded polynucleotides that serve as templates.
- Primers then anneal to each nucleic strand at a temperature between 40° C. and 75° C. to demarcate a target sequence for the polymerase-catalyzed attachment of the appropriate dNTP. Repeated cycling of these processes (thermal cycling) results in quantities of nucleic acid sufficient for analysis.
- a unitary container is important for increasing the specificity of the PCR amplification and for increasing the shelf life of any pre-mixed PCR reagents in the container.
- U.S. Pat. No. 5,411,876 discloses a technique preparatory to PCR that interposes a barrier into the PCR reaction vessel.
- the barrier in the '876 patent is composed of a hydrophobic substance, such as a grease or wax.
- One purpose of the barrier is to preserve reagent concentration during heating by attempting to prevent solvent evaporating from the PCR reaction tube.
- the melting point of the wax is chosen so that the less-dense molten wax floats on the surface of the solvent during PCR thermal cycling.
- the solidified wax seals the reagents from the environment. If the PCR reaction tube is opened after amplification, the solidified wax barrier prevents both endogenous nucleic acid from escaping and endogenous nucleic acid from comingling with the endogenous nucleic acid.
- a disadvantage of this method is that the addition of the hydrophobic material adds a handling step that poses a risk of contamination.
- a second purpose of the technique disclosed in the '876 patent is to pre-fill a PCR reaction vessel with reagents necessary for DNA amplification in a batch process.
- Batch processing removes a handling step by eliminating the necessity of adding the hydrophobic material during PCR thermal cycling, enables more accurate control over the addition of reagents, and creates a stockpile of PCR reaction tubes for future use.
- a wax barrier segregates one or more necessary reagents from the remaining reagents.
- the melting point of the wax is chosen such that the wax is solid at storage temperatures of about 0° C. to 5° C. Heating the PCR reaction tube above about 40° C. causes the wax to melt, releasing the sequestered reagent and initiating the PCR process.
- Segregation of selected PCR reagents inhibits primer oligomerization and extends the stability of the reagent mixture from only a few days to a week or more. The segregation also minimizes annealing of primers to non-target sequences, which reduces the yield of amplified target sequences. If reagents are combined prior to the start of thermal cycling, mispriming occurs in an admixture of the nucleic acid to be amplified.
- a limitation of the invention disclosed in the '876 patent is that the disclosed vessel is not intended for prolonged storage of the contained reagents near room temperature.
- the container and method cannot be used with the intact biological specimen to be analyzed, but is limited to use with the nucleic acids that have already been extracted from the biological specimen, requiring at least one manipulation step, during which contamination or error can occur.
- the PCR reaction tube must be sized to fit the PCR instrument(s).
- the inventive method and apparatus permit the collection, transport and identification of a specimen that contains nucleic acid, while also controlling exposure of the specimen to all reagents that will be needed for processing and analyses of the specimen using the polymerase chain reaction.
- the present invention permits temporal selectivity for processing and analyses.
- the present invention reduces fabrication costs by eliminating the need for a frangible barrier or a complicated container geometry.
- Many containers incorporating the present invention can be prepared by batch processing. This enables reproducible reagent compositions and reduces the cost and time involved to prepare individual containers.
- FIG. 1 is a perspective view of one embodiment of the container according to the principles of the present invention.
- FIG. 2 is an axial cross-sectional view of the container shown in FIG. 1.
- FIG. 3 is an axial cross-sectional view of an alternate embodiment of the container according to the invention.
- FIG. 4A is a photograph of a membrane containing nucleic acid from blood samples stored for various times according to the invention.
- FIG. 4B is a photograph of a membrane containing nucleic acid from hair samples stored for various times according to the invention.
- FIG. 5 is a photograph of a membrane containing nucleic acid from samples stored at various temperatures.
- FIGS. 6A through 6F are photographs of electrophoretically separated nucleic acid profiles.
- an apparatus in accordance with the principles of the present invention includes a container 10 .
- the container 10 has a closed curved end 14 , an open end 16 that can be securely sealed, such as by a tight-fitting cap 18 , and a container wall 20 .
- the open end 16 is distal to the closed end 14 so that the container wall 20 defines an enclosed volume 12 .
- the container wall 20 must be constructed of a chemically inert material that can withstand temperatures in the range of about 20° to 100° C. Polypropylene is one such material, but other materials can also be used without departing from the spirit and scope of the present invention.
- container 10 incorporates a barrier 30 to isolate at least one reagent 40 from a headspace 11 above the barrier 30 .
- One or more reagents 40 used in the polymerase chain reaction (PCR) are contained in the enclosed volume 12 .
- the volume of reagents can vary as long as the total volume can be contained while still leaving adequate space for addition of sample, but preferably a reagent volume of about 0.5 ml is used.
- the reagents can be lysing reagents, amplifying reagents, photo-sterilizing reagents, detecting reagents, and combinations thereof. Lysing reagents disrupt the cellular walls of a specimen containing nucleic acids.
- a typical combination of lysing reagents includes a buffer, a detergent, and a protease. Photo-sterilizing reagents prevent the use of nucleic acid as a template for subsequent reactions.
- a typical photo-sterilizing reagent includes a photo-reagent and a chelator to remove magnesium ions.
- Amplifying reagents typically a buffer, four deoxyribonucleoside triphosphates, a magnesium compound, a polynucleotide polymerase enzyme and at least one oligonucleotide primer, are used to increase the amount of nucleic acid in a specimen by replicating the nucleic acid.
- Detecting reagents are substances that carry an analytical signal generator, for example, a radioisotope or magnetic particles, that facilitates detection and separation of the amplified nucleic acid from other components of the reaction mixture.
- barrier 30 is interposed between the reagents 40 and the headspace 11 .
- the barrier is such that if a specimen 50 is introduced into the headspace 11 above the barrier 30 , the reagents 40 do not contact the specimen and thus cannot react with it.
- the barrier 30 is composed of a hydrophobic material that, when breached, releases the reagents 40 from confinement. Breach of the barrier can occur by any number of methods to change the physical integrity of the barrier 30 , but most preferably occurs by application of an energy source such as heat.
- the container 10 is then agitated by either a manual or automated method, to mix the specimen with the reagents 40 and to promote a complete reaction.
- the barrier 30 is generated by adding molten wax to the container 10 containing the desired reagents 40 .
- a volume of wax of about 0.050 ml is adequate for a container that can accommodate a volume of 0.5 ml of reagent.
- the wax is then allowed to solidify and a specimen 50 is added to the container 10 .
- the container 10 is then closed in a manner to eliminate release of the specimen 50 from the container 10 and to prevent contamination of the specimen 50 by extraneous agents or objects.
- the barrier 30 is breached by heating the container 10 above the melting point of the wax barrier 30 . Since the wax is less dense than the solution, the molten wax will float on the surface of the solution. As the container 10 cools, the wax will solidify to form a seal that overlaps and hence protects the mixture of sample and reagents.
- a second wax barrier 60 and a second reagent 70 may be added to the container 10 .
- a container is prepared containing reagents and barrier, as previously described.
- a second reagent 70 is added to the container 10 and accumulates above the first barrier 30 in a section of the headspace 11 within the enclosed volume 12 . The sample is then added.
- each barrier 30 , 60 can be individually breached by the application of an energy source.
- a second wax barrier 60 is generated by pouring molten wax having a melting point that is at least about 5° C., and preferably about 10° C. different from the melting point of the first barrier 30 into the container 10 . The wax is then allowed to solidify.
- the melting point of the wax of the first barrier 30 must be less than the melting point of the wax of the second barrier 60 if premixing of the two reagents 40 , 70 is desired before sample 50 contained within the vessel is mixed.
- the melting point of the wax constituting the first barrier 30 is greater than the melting point of the wax of the second barrier 60 , the second reagent 70 will contact the sample as the container is heated and the first reagent 40 will remain confined.
- the present invention may incorporate a plurality of wax barriers 60 , each isolating a reagent 70 .
- the melting point of each wax is discrete and chosen such that each reagent can be individually released with discretion by selecting the appropriate temperature to which the vessel is exposed.
- a kit, prepared in accordance with the present invention can be used to collect a set of specimens 50 for nucleic acid identification.
- the kit contains at least one of the inventive vessels, and preferably at least two vessels, as described.
- Specimens 50 are added to the container above the barrier 30 .
- the preferred barrier 30 is wax with a melting point of about 55° C. that has been presterilized and is in a volume of about 50 ⁇ l.
- the reagent is a lysing reagent that includes a buffer, a detergent, and a protease.
- Typical specimens 50 inserted into the container are hair, blood or cells from the mucous membranes of the oral cavity, commonly termed buccal swabs.
- hair it is preferable to have at least about 10 to 30 hairs and the hairs must include roots.
- a volume of about 10-100 ⁇ l is sufficient.
- mucosal cells the cell may be obtained by swabbing the inner cheek membrane with a cotton-tipped swab and, in that case, the swab tip containing the cells may be removed from the handle of the swab and placed into the vessel 10 .
- a label 100 having a unique identifier, for example a bar code, and a tamper resistant seal are also affixed to each vessel 10 (FIG. 1).
- the vessels 10 are placed in a transport holder to which an identifier, for example a bar code, and a tamper resistant seal are affixed.
- the containers 10 are packaged and transported to an analytical laboratory, preferably using a pre-addressed envelope. Upon receipt at the analytical laboratory, the integrity and identifier of the transport holder are verified and the receipt of the container 10 carrying the specimens 50 is noted.
- the sealed tubes are transported to a clean room environment within the laboratory. After confirmation of the container identity and any other preparative steps, such as assembly of equipment, the container 10 , still sealed, is heated to a temperature in the range of the melting temperature of the wax barrier 30 for a defined time. Preferably, intermittent mixing is performed during the melting process. The melted wax, being inert, does not affect either the specimen or the reagents.
- the container 10 may be opened to add nucleic acid extraction reagents.
- One advantage of the present invention is that it permits temporal selectivity for processing and analyses of a specimen 50 . It is preferred to delay the exposure of specimen 50 to reagents until immediately before analysis.
- the container 10 of the present invention permits discretion over the time of mixing the specimen 50 and segregated reagents, as temperatures sufficient to breach the barrier will not occur absent application of heat.
- Another advantage of the present invention is that it eliminates the need for a complex container geometry or mechanism to isolate the reagent from the specimen 50 .
- the barrier accomplishes the same function as “container within a container” vessels, yet does not fragment upon breach as does a frangible container, and is functionally simple and relatively inexpensive in comparison.
- the barrier is wax, the same wax that is used as an original barrier is used to reseal the contents in the container after processing to prevent contamination by exogenous nucleic acid.
- the present invention is both cost and time saving, since fewer laboratory manipulation steps are required in specimen collection, processing, and analysis.
- Specimens 50 can be collected from deceased or living humans, and specimen volume is not critical. Specimens 50 can be collected on diverse media, for example, filter paper, cotton swabs, cigarette butts, gum, or other media. The physical state of the specimen 50 is not critical, for example, coagulated blood is acceptable, thus broadening the range of specimens that can be collected. Solids or liquids may be collected and placed into the container 10 . Further details and embodiments of the invention will be described in the following examples.
- the reagent retained by the upper wax barrier was a proteinase K solution (0.51 ml) composed of 0.4 ml TNE (1 mm Tris, pH 7.5, 50 mM NaCl, 0.5 mM EDTA), 0.025 ml sodium dodecyl sulfate (SDS) 20%, 0.075 ml sterile deionized water, and 0.010 ml proteinase K (20 mg/ml). All samples were collected and inserted into the vessels at the same time. Nucleic acid for blood and hair samples was extracted immediately and also after one week of storage at room temperature (25° C.). The stored samples simulated conditions during which specimens may be held prior to analysis, e.g., during shipment.
- the vessels containing the now digested samples were incubated at 70° C. to melt the lower wax barrier and permit the formerly confined extraction reagent (phenol:chloroform:isoamylalcohol 25:24:1) (0.5 ml) to mix with the digested samples.
- the contents of each vessel were then mixed by briefly vortexing.
- the upper aqueous phase was transferred to a fresh sterile 1.5 ml test tube using a sterile pipette. Residual chloroform was evaporated by incubating the open container containing the extracted nucleic acid at about 60° C. for about 1 hour.
- the extracted nucleic acid was then microconcentrated.
- the solution (about 500 ml) was transferred, using a sterile pipette or other means, into a Microcon 100 microconcentrator (Millipore) and centrifuged at about 500 ⁇ g (about 2475 rpm) for about 15 min.
- the microconcentrator was then inverted in a sterile 1.5 ml tube and the microconcentrate was collected by centrifugation at a maximum speed for about 2 min.
- Nucleic acid in the samples was quantitated by spotting the microconcentrate on a Biodyne B membrane.
- Known human DNA standards of 2 ng, 1 ng, and 0.5 ng in a volume of 5 ⁇ l were placed on the membrane in order to compare the samples.
- About 5 ⁇ l of each sample were added to 0.15 ml of spotting solution (0.4 N NaOH, 25 mM EDTA, 0.00008% bromothymol blue).
- the samples were spotted onto the pre-wetted (0.4 N NaOH, 25 mM EDTA) Biodyne B membrane secured in a vacuum manifold. A vacuum was applied to the apparatus containing the membrane with the samples spotted thereon for about 1 min.
- the membrane was placed in 50 ml of hybridization solution (5X SSPE, 0.5% w/v SDS), including 2.5 ml of 30% hydrogen peroxide (H 2 O 2 ). The membrane was incubated for about 15 min. at about 55° C. with gentle agitation. The solution was removed, preferably by pouring the solution off the membrane, and 30 ml of hybridization solution containing 0.02 ml D17Z1 human specific probe was added. The membrane was incubated for about 20 min. at about 50° C. with gentle agitation. The hybridization solution was then removed as previously described, and rinsed with 100 ml wash solution (1.5X SSPE, 0.5% SDS) for 1 min.
- 5X SSPE, 0.5% w/v SDS including 2.5 ml of 30% hydrogen peroxide (H 2 O 2 ).
- the membrane was incubated for about 15 min. at about 55° C. with gentle agitation.
- the solution was removed, preferably by pouring the solution off the membrane, and 30 ml of
- wash solution containing 180 ⁇ l enzyme conjugate:HRP-SA was added and incubated at about 50° C. for about 10 min. with agitation.
- the enzyme solution was removed and the membrane washed with 100 ml of wash solution for 15 min. at about 22° C. (room temperature) with agitation.
- the membrane was then washed with 0.1 M sodium citrate, pH 5 for 1 min. and removed.
- Development solution (30 ml citrate buffer containing 1.5 ml of the chromagen:TMB and 3% H 2 O 2 was added, and the membrane was incubated in the dark at room temperature for 20 min. The development solution was removed, and the color reaction was stopped by adding deionized water. The membrane was then photographed.
- FIGS. 4A blood and 4 B (hair).
- FIG. 4A there did not appear to be any significant difference between amounts of nucleic acid that were extracted from a fresh sample of blood, as shown adjacent the upper bracket, or a sample of blood that had been stored at 22° C. (room temperature) for 1 week in the container of the present invention, as shown adjacent the lower bracket.
- FIG. 4B there did not appear to be any significant difference in two of the samples between amounts of nucleic acid that were extracted from three fresh hairs, as shown adjacent the upper bracket, or a sample of three hairs that had been stored at 22° C. (room temperature) for 1 week in the vessel of the present invention, as shown adjacent the lower bracket.
- the stored samples showed an even darker band than the freshly extracted samples.
- the temperatures were selected to represent standard storage or transit temperatures; simulating refrigeration conditions (about 4° C.), room temperature conditions (about 25° C.), and in vivo conditions (about 37° C.). Nucleic acids were extracted as previously described. Analysis of each sample was performed in duplicate.
- column III from top to bottom, is nucleic acid extracted from blood samples stored in the inventive vessel at 4° C., 25° C., and 37° C.
- the middle three lines sequentially represent the nucleic acid extracted by the barrier method from epithelial cells stored at 4° C., 25° C., and 37° C.
- the bottom three lines sequentially represent the nucleic acid extracted by the barrier method from blood stored at 4° C. and 25° C.
- from top to bottom are nucleic acid extracted from hair stored at 37° C. using a conventional method first (top band) and from the inventive method (second band).
- the results of the nucleic acid analyses indicated that samples stored either at about 4° C. or about 37° C. for three days generated similar quantities of nucleic acid, ranging from 1 to 5 ng/ ⁇ l, for all three specimens. Additionally, further analyses indicated that the same quantity of DNA was generated from samples stored 3 days at 4° C., 25° C., or 37° C. (FIG. 3). For example, nucleic acid profiles from hair stored in the inventive vessel at either 4° C. or 37° C. were indistinguishable (data not shown).
- FIGS. 6 A- 6 F nucleic acid profiles were generated using an AmpF/STRTM Profiler Plus PCR reaction kit that amplifies ten genetic loci for purposes of human identification.
- FIGS. 6 A- 6 C are the ten genetic loci for nucleic acid profiles generated from blood samples according to the inventive method.
- FIGS. 6 D- 6 F are the ten genetic loci for nucleic acid profiles generated from blood samples collected by conventional organic extraction methodology, as is known to one skilled in the art. The results between the methods are virtually indistinguishable.
- the container of the invention can be used for extraction and subsequent analysis of nucleic acid from either whole blood (either anticoagulated or coagulated), epithelial cells from the oral mucosa (buccal swabs), or hairs with intact roots.
- the nucleic acids extracted can be used to generate human profiles such as DNA profiles.
- the inventive vessel allows sample and storage for subsequent nucleic acid extraction and analysis in a unitary, self-contained system.
- Use of the vessel reduces hands-on time, which in turn reduces the risk of contamination, benefits long term storage, is amenable to different types of samples, and is cost effective.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An apparatus and method for temporally regulating analysis of nucleic acids in a specimen. The specimen, such as blood or hair, is contained in a vessel pre-packaged with all reagents needed for the analysis, having one or more barriers that can be selectively breached. Preferably, the barrier is a wax having a discrete melting point. The vessel may be stored until specimen is added, then the vessel containing the specimen can again be stored. Breaching the barrier allows the user to select when reagents will contact the specimen. A number of barriers can be incorporated to segregate a number of reagents. This invention provides a simple, self-contained and portable vessel for collecting, transporting, and processing a specimen for nucleic acid analysis at a desired time. The invention also avoids sample and environmental contamination.
Description
- This invention relates to a method and apparatus to temporally regulate analysis of a nucleic acid.
- For nucleic acid analysis of biological samples, the collected samples are routinely stored in various containers. After collection of the specimen, such as blood or hair, the container is usually sealed to isolate the specimen from the environment until analysis is performed. If analysis is postponed or if off-site analysis is to be performed, some samples may be maintained in a controlled environment in order to sustain specimen integrity. Further, the container must be rugged enough to withstand transit and storage without compromising the specimen. For example, samples collected at crime scenes must be accurately identified and described, and transported to a lab for subsequent analysis.
- The potential for error in maintaining, labeling, handling, etc. a sample increases with the number of manipulative steps involved. Sample contamination is a concern since, as the specimen is processed, the sample is manipulated with the risk of identification error and/or sample contamination from exogenous nucleic acid, as nucleic acids are ubiquitous and contamination may occur from innocuous sources such as dust. Likewise, environmental contamination may be a concern, since a blood sample could contaminate the surrounding environment. Each time that the specimen is transferred, manipulated, etc., there is an opportunity to misidentify the specimen, contaminate the specimen or contaminate the environment. In addition, the container or specimen could be potentially misidentified or misplaced with each handling step, resulting in incorrect or incomplete sample identification.
- Biological samples often are subjected to nucleic acid analysis to identify the source of the sample, or to identify one or more features of a sample. A standard analytical tool for nucleic acid analysis of specimens is the polymerase chain reaction (PCR). The basis of PCR is that it exponentially multiplies the quantity of nucleic acid extracted from a specimen to generate a quantity sufficient for analysis. PCR requires multiple reagents appropriate for amplification, such as a buffer, all four deoxyribonucleoside triphosphates (dNTP) (i.e., adenine triphosphate or dATP, thymine triphosphate or dTTP, cytosine triphosphate or dCTP, and guanine triphosphate or dGTP), magnesium, a polynucleotide polymerase enzyme, and at least one oligonucleotide primer.
- Initially, nucleic acid is extracted from a specimen and added to the above reagents. The nucleic acid is denatured at a temperature between 90° C. and 100° C. to create two single-stranded polynucleotides that serve as templates. Primers then anneal to each nucleic strand at a temperature between 40° C. and 75° C. to demarcate a target sequence for the polymerase-catalyzed attachment of the appropriate dNTP. Repeated cycling of these processes (thermal cycling) results in quantities of nucleic acid sufficient for analysis.
- Since PCR exponentially multiplies any nucleic acid present, whether endogenous or exogenous to the sample, samples to undergo PCR must be handled with the utmost care. Any exogenous nucleic acid present not only contaminates the specimen, but will be amplified during PCR, yielding an incorrect analysis. Since any contaminant nucleic acid is amplified, it is easy to appreciate why even trace contamination of the sample is fatal to obtaining an accurate result.
- A unitary container is important for increasing the specificity of the PCR amplification and for increasing the shelf life of any pre-mixed PCR reagents in the container. U.S. Pat. No. 5,411,876 discloses a technique preparatory to PCR that interposes a barrier into the PCR reaction vessel. The barrier in the '876 patent is composed of a hydrophobic substance, such as a grease or wax. One purpose of the barrier is to preserve reagent concentration during heating by attempting to prevent solvent evaporating from the PCR reaction tube. The melting point of the wax is chosen so that the less-dense molten wax floats on the surface of the solvent during PCR thermal cycling. After amplification, the solidified wax seals the reagents from the environment. If the PCR reaction tube is opened after amplification, the solidified wax barrier prevents both endogenous nucleic acid from escaping and endogenous nucleic acid from comingling with the endogenous nucleic acid. A disadvantage of this method, however, is that the addition of the hydrophobic material adds a handling step that poses a risk of contamination.
- A second purpose of the technique disclosed in the '876 patent is to pre-fill a PCR reaction vessel with reagents necessary for DNA amplification in a batch process. Batch processing removes a handling step by eliminating the necessity of adding the hydrophobic material during PCR thermal cycling, enables more accurate control over the addition of reagents, and creates a stockpile of PCR reaction tubes for future use. A wax barrier segregates one or more necessary reagents from the remaining reagents. The melting point of the wax is chosen such that the wax is solid at storage temperatures of about 0° C. to 5° C. Heating the PCR reaction tube above about 40° C. causes the wax to melt, releasing the sequestered reagent and initiating the PCR process. Segregation of selected PCR reagents inhibits primer oligomerization and extends the stability of the reagent mixture from only a few days to a week or more. The segregation also minimizes annealing of primers to non-target sequences, which reduces the yield of amplified target sequences. If reagents are combined prior to the start of thermal cycling, mispriming occurs in an admixture of the nucleic acid to be amplified.
- A limitation of the invention disclosed in the '876 patent is that the disclosed vessel is not intended for prolonged storage of the contained reagents near room temperature. In addition, the container and method cannot be used with the intact biological specimen to be analyzed, but is limited to use with the nucleic acids that have already been extracted from the biological specimen, requiring at least one manipulation step, during which contamination or error can occur. Still another limitation is that the PCR reaction tube must be sized to fit the PCR instrument(s).
- It is known to pre-fill sample containers with a reagent to conveniently process a specimen added to the container. To control exposure of the specimen added to the container, the reagent can be enclosed within a secondary frangible container contained within the primary sample container. The reagent is then released by rupture of the frangible container, and is subsequently mixed with the sample while confined within the primary sample container. One disadvantage of this method is that fragments from the frangible container can contact and hence contaminate the sample. Another disadvantage of this method is the addition of a costly manufacturing step to produce the intricate “container within a container” assembly. Although some pre-filled sample containers eliminate the frangible barrier, these are usually not amenable for use in an analytical instrument.
- Thus, what is ideally desired is a simple, portable and inexpensive method and apparatus to allow the user to temporally regulate the analysis of a specimen containing a nucleic acid.
- The inventive method and apparatus permit the collection, transport and identification of a specimen that contains nucleic acid, while also controlling exposure of the specimen to all reagents that will be needed for processing and analyses of the specimen using the polymerase chain reaction. By employing one or more breachable barriers to segregate one or more reagents from the specimen, the present invention permits temporal selectivity for processing and analyses. The present invention reduces fabrication costs by eliminating the need for a frangible barrier or a complicated container geometry. Many containers incorporating the present invention can be prepared by batch processing. This enables reproducible reagent compositions and reduces the cost and time involved to prepare individual containers.
- Other advantages and features of the present invention will be appreciated with reference to the following drawings, detailed description, and examples.
- FIG. 1 is a perspective view of one embodiment of the container according to the principles of the present invention.
- FIG. 2 is an axial cross-sectional view of the container shown in FIG. 1.
- FIG. 3 is an axial cross-sectional view of an alternate embodiment of the container according to the invention.
- FIG. 4A is a photograph of a membrane containing nucleic acid from blood samples stored for various times according to the invention.
- FIG. 4B is a photograph of a membrane containing nucleic acid from hair samples stored for various times according to the invention.
- FIG. 5 is a photograph of a membrane containing nucleic acid from samples stored at various temperatures.
- FIGS. 6A through 6F are photographs of electrophoretically separated nucleic acid profiles.
- Referring to FIG. 1, an apparatus in accordance with the principles of the present invention includes a container 10. In one embodiment, the container 10 has a closed
curved end 14, anopen end 16 that can be securely sealed, such as by a tight-fitting cap 18, and acontainer wall 20. Theopen end 16 is distal to theclosed end 14 so that thecontainer wall 20 defines anenclosed volume 12. Thecontainer wall 20 must be constructed of a chemically inert material that can withstand temperatures in the range of about 20° to 100° C. Polypropylene is one such material, but other materials can also be used without departing from the spirit and scope of the present invention. - Referring to FIG. 2, container 10 incorporates a
barrier 30 to isolate at least onereagent 40 from a headspace 11 above thebarrier 30. One ormore reagents 40 used in the polymerase chain reaction (PCR) are contained in theenclosed volume 12. The volume of reagents can vary as long as the total volume can be contained while still leaving adequate space for addition of sample, but preferably a reagent volume of about 0.5 ml is used. - The reagents can be lysing reagents, amplifying reagents, photo-sterilizing reagents, detecting reagents, and combinations thereof. Lysing reagents disrupt the cellular walls of a specimen containing nucleic acids. A typical combination of lysing reagents includes a buffer, a detergent, and a protease. Photo-sterilizing reagents prevent the use of nucleic acid as a template for subsequent reactions. A typical photo-sterilizing reagent includes a photo-reagent and a chelator to remove magnesium ions. Amplifying reagents, typically a buffer, four deoxyribonucleoside triphosphates, a magnesium compound, a polynucleotide polymerase enzyme and at least one oligonucleotide primer, are used to increase the amount of nucleic acid in a specimen by replicating the nucleic acid. Detecting reagents are substances that carry an analytical signal generator, for example, a radioisotope or magnetic particles, that facilitates detection and separation of the amplified nucleic acid from other components of the reaction mixture.
- After
reagents 40, such as those previously mentioned, are added to the container 10,barrier 30 is interposed between thereagents 40 and the headspace 11. The barrier is such that if aspecimen 50 is introduced into the headspace 11 above thebarrier 30, thereagents 40 do not contact the specimen and thus cannot react with it. Thebarrier 30 is composed of a hydrophobic material that, when breached, releases thereagents 40 from confinement. Breach of the barrier can occur by any number of methods to change the physical integrity of thebarrier 30, but most preferably occurs by application of an energy source such as heat. The container 10 is then agitated by either a manual or automated method, to mix the specimen with thereagents 40 and to promote a complete reaction. - In one embodiment, the
barrier 30 is generated by adding molten wax to the container 10 containing the desiredreagents 40. A volume of wax of about 0.050 ml is adequate for a container that can accommodate a volume of 0.5 ml of reagent. The wax is then allowed to solidify and aspecimen 50 is added to the container 10. The container 10 is then closed in a manner to eliminate release of thespecimen 50 from the container 10 and to prevent contamination of thespecimen 50 by extraneous agents or objects. At a desired time, thebarrier 30 is breached by heating the container 10 above the melting point of thewax barrier 30. Since the wax is less dense than the solution, the molten wax will float on the surface of the solution. As the container 10 cools, the wax will solidify to form a seal that overlaps and hence protects the mixture of sample and reagents. - Referring to FIG. 3, in an alternate embodiment of the invention, a
second wax barrier 60 and asecond reagent 70 may be added to the container 10. In this case, a container is prepared containing reagents and barrier, as previously described. However, before addition of sample, asecond reagent 70 is added to the container 10 and accumulates above thefirst barrier 30 in a section of the headspace 11 within theenclosed volume 12. The sample is then added. - In this embodiment, each
30, 60 can be individually breached by the application of an energy source. For example, in one embodiment abarrier second wax barrier 60 is generated by pouring molten wax having a melting point that is at least about 5° C., and preferably about 10° C. different from the melting point of thefirst barrier 30 into the container 10. The wax is then allowed to solidify. The melting point of the wax of thefirst barrier 30 must be less than the melting point of the wax of thesecond barrier 60 if premixing of the two 40, 70 is desired beforereagents sample 50 contained within the vessel is mixed. Likewise, if the melting point of the wax constituting thefirst barrier 30 is greater than the melting point of the wax of thesecond barrier 60, thesecond reagent 70 will contact the sample as the container is heated and thefirst reagent 40 will remain confined. - It will be understood that the present invention may incorporate a plurality of
wax barriers 60, each isolating areagent 70. The melting point of each wax is discrete and chosen such that each reagent can be individually released with discretion by selecting the appropriate temperature to which the vessel is exposed. - A kit, prepared in accordance with the present invention, can be used to collect a set of
specimens 50 for nucleic acid identification. The kit contains at least one of the inventive vessels, and preferably at least two vessels, as described.Specimens 50 are added to the container above thebarrier 30. In one embodiment, the preferredbarrier 30 is wax with a melting point of about 55° C. that has been presterilized and is in a volume of about 50 μl. The reagent is a lysing reagent that includes a buffer, a detergent, and a protease. -
Typical specimens 50 inserted into the container are hair, blood or cells from the mucous membranes of the oral cavity, commonly termed buccal swabs. For hair, it is preferable to have at least about 10 to 30 hairs and the hairs must include roots. For blood, a volume of about 10-100 μl is sufficient. For mucosal cells, the cell may be obtained by swabbing the inner cheek membrane with a cotton-tipped swab and, in that case, the swab tip containing the cells may be removed from the handle of the swab and placed into the vessel 10. - A
label 100 having a unique identifier, for example a bar code, and a tamper resistant seal are also affixed to each vessel 10 (FIG. 1). The vessels 10 are placed in a transport holder to which an identifier, for example a bar code, and a tamper resistant seal are affixed. The containers 10 are packaged and transported to an analytical laboratory, preferably using a pre-addressed envelope. Upon receipt at the analytical laboratory, the integrity and identifier of the transport holder are verified and the receipt of the container 10 carrying thespecimens 50 is noted. - For initiation of the nucleic acid analysis, the sealed tubes are transported to a clean room environment within the laboratory. After confirmation of the container identity and any other preparative steps, such as assembly of equipment, the container 10, still sealed, is heated to a temperature in the range of the melting temperature of the
wax barrier 30 for a defined time. Preferably, intermittent mixing is performed during the melting process. The melted wax, being inert, does not affect either the specimen or the reagents. - Once the
barrier 30 has melted to an extent whereby thespecimen 50 to be analyzed and the lysing reagent make contact, the container 10 may be opened to add nucleic acid extraction reagents. - One advantage of the present invention is that it permits temporal selectivity for processing and analyses of a
specimen 50. It is preferred to delay the exposure ofspecimen 50 to reagents until immediately before analysis. The container 10 of the present invention permits discretion over the time of mixing thespecimen 50 and segregated reagents, as temperatures sufficient to breach the barrier will not occur absent application of heat. - Another advantage of the present invention is that it eliminates the need for a complex container geometry or mechanism to isolate the reagent from the
specimen 50. The barrier accomplishes the same function as “container within a container” vessels, yet does not fragment upon breach as does a frangible container, and is functionally simple and relatively inexpensive in comparison. In addition, if the barrier is wax, the same wax that is used as an original barrier is used to reseal the contents in the container after processing to prevent contamination by exogenous nucleic acid. - The present invention is both cost and time saving, since fewer laboratory manipulation steps are required in specimen collection, processing, and analysis.
-
Specimens 50 can be collected from deceased or living humans, and specimen volume is not critical.Specimens 50 can be collected on diverse media, for example, filter paper, cotton swabs, cigarette butts, gum, or other media. The physical state of thespecimen 50 is not critical, for example, coagulated blood is acceptable, thus broadening the range of specimens that can be collected. Solids or liquids may be collected and placed into the container 10. Further details and embodiments of the invention will be described in the following examples. - Stability of nucleic acids contained in samples contained in the inventive vessel over a one week period of time at 25° C. was evaluated. Using a vessel according to an embodiment of the invention having two wax barriers isolating separate reagents, either samples of whole blood (100 ml) or samples of hair with roots (10-20) were placed in the vessel on top of the upper wax barrier. The reagent retained by the upper wax barrier was a proteinase K solution (0.51 ml) composed of 0.4 ml TNE (1 mm Tris, pH 7.5, 50 mM NaCl, 0.5 mM EDTA), 0.025 ml sodium dodecyl sulfate (SDS) 20%, 0.075 ml sterile deionized water, and 0.010 ml proteinase K (20 mg/ml). All samples were collected and inserted into the vessels at the same time. Nucleic acid for blood and hair samples was extracted immediately and also after one week of storage at room temperature (25° C.). The stored samples simulated conditions during which specimens may be held prior to analysis, e.g., during shipment.
- Extraction of nucleic acid from the samples was initiated by incubating the vessels containing the samples at 55° C. for two hours, with intermittent mixing of the samples and reagents by placing the vessels on a vortex for a few seconds every 30 minutes. The vessels were evaluated at the end of the incubation to ensure that the upper wax barrier had melted and that the specimens had mixed with the proteinase K digestion solution. Nucleic acid extraction then proceeded according to the following methods.
- The vessels containing the now digested samples were incubated at 70° C. to melt the lower wax barrier and permit the formerly confined extraction reagent (phenol:chloroform:isoamylalcohol 25:24:1) (0.5 ml) to mix with the digested samples. The contents of each vessel were then mixed by briefly vortexing. The upper aqueous phase was transferred to a fresh sterile 1.5 ml test tube using a sterile pipette. Residual chloroform was evaporated by incubating the open container containing the extracted nucleic acid at about 60° C. for about 1 hour.
- The extracted nucleic acid was then microconcentrated. The solution (about 500 ml) was transferred, using a sterile pipette or other means, into a
Microcon 100 microconcentrator (Millipore) and centrifuged at about 500×g (about 2475 rpm) for about 15 min. A buffer solution of 10 mM Tris and 1 mM EDTA (0.2 ml) was added to the microconcentrator and centrifugation was repeated for 5 minutes using the same conditions as previously described. The microconcentrator was then inverted in a sterile 1.5 ml tube and the microconcentrate was collected by centrifugation at a maximum speed for about 2 min. - Nucleic acid in the samples was quantitated by spotting the microconcentrate on a Biodyne B membrane. Known human DNA standards of 2 ng, 1 ng, and 0.5 ng in a volume of 5 μl were placed on the membrane in order to compare the samples. About 5 μl of each sample were added to 0.15 ml of spotting solution (0.4 N NaOH, 25 mM EDTA, 0.00008% bromothymol blue). The samples were spotted onto the pre-wetted (0.4 N NaOH, 25 mM EDTA) Biodyne B membrane secured in a vacuum manifold. A vacuum was applied to the apparatus containing the membrane with the samples spotted thereon for about 1 min. to ensure that all the nucleic acid solution had been incorporated through the membrane. The membrane was placed in 50 ml of hybridization solution (5X SSPE, 0.5% w/v SDS), including 2.5 ml of 30% hydrogen peroxide (H 2O2). The membrane was incubated for about 15 min. at about 55° C. with gentle agitation. The solution was removed, preferably by pouring the solution off the membrane, and 30 ml of hybridization solution containing 0.02 ml D17Z1 human specific probe was added. The membrane was incubated for about 20 min. at about 50° C. with gentle agitation. The hybridization solution was then removed as previously described, and rinsed with 100 ml wash solution (1.5X SSPE, 0.5% SDS) for 1 min. After about 1 min, 30 ml of wash solution containing 180 μl enzyme conjugate:HRP-SA was added and incubated at about 50° C. for about 10 min. with agitation. The enzyme solution was removed and the membrane washed with 100 ml of wash solution for 15 min. at about 22° C. (room temperature) with agitation. The membrane was then washed with 0.1 M sodium citrate, pH 5 for 1 min. and removed. Development solution (30 ml citrate buffer containing 1.5 ml of the chromagen:TMB and 3% H2O2 was added, and the membrane was incubated in the dark at room temperature for 20 min. The development solution was removed, and the color reaction was stopped by adding deionized water. The membrane was then photographed.
- The results are presented in FIGS. 4A (blood) and 4B (hair). As shown in FIG. 4A, there did not appear to be any significant difference between amounts of nucleic acid that were extracted from a fresh sample of blood, as shown adjacent the upper bracket, or a sample of blood that had been stored at 22° C. (room temperature) for 1 week in the container of the present invention, as shown adjacent the lower bracket. As shown in FIG. 4B, there did not appear to be any significant difference in two of the samples between amounts of nucleic acid that were extracted from three fresh hairs, as shown adjacent the upper bracket, or a sample of three hairs that had been stored at 22° C. (room temperature) for 1 week in the vessel of the present invention, as shown adjacent the lower bracket. In one of the samples, the stored samples showed an even darker band than the freshly extracted samples.
- Stability of nucleic acid to various temperatures was evaluated using samples of whole blood (about 100 μl), hairs including hair roots (10-20), and epithelial cells from the oral mucosa (cotton tip from a buccal swab). The blood and hair samples were placed into the vessel of the invention directly on the wax barrier segregating the extraction solution, as previously described. The cotton tip of the collection apparatus was removed from the holder and the tips were likewise placed in the vessel on the wax barrier. Vessels containing respective samples were incubated at about 4° C., 25° C., or 37° C. for 3 days. The temperatures were selected to represent standard storage or transit temperatures; simulating refrigeration conditions (about 4° C.), room temperature conditions (about 25° C.), and in vivo conditions (about 37° C.). Nucleic acids were extracted as previously described. Analysis of each sample was performed in duplicate.
- The results are presented in FIG. 5. In column I, from top to bottom are human nucleic acid standards of 2 ng, 1 ng, 0.5 ng, 0.25 ng, and 0.125 ng in a volume of 5 μl. In column II, from top to bottom are nucleic acid extracted from blood stored at 4° C., 25° C., and 37° C., the middle three lines sequentially represent the nucleic acid extracted by a conventional method from epithelial cells stored at 4° C., 25° C., and 37° C., and the bottom three lines sequentially represent the nucleic acid extracted by a conventional method from hair stored at 4° C. and 25° C. In column III, from top to bottom, is nucleic acid extracted from blood samples stored in the inventive vessel at 4° C., 25° C., and 37° C., the middle three lines sequentially represent the nucleic acid extracted by the barrier method from epithelial cells stored at 4° C., 25° C., and 37° C., and the bottom three lines sequentially represent the nucleic acid extracted by the barrier method from blood stored at 4° C. and 25° C. In column IV, from top to bottom are nucleic acid extracted from hair stored at 37° C. using a conventional method first (top band) and from the inventive method (second band).
- As shown in FIG. 5, the results of the nucleic acid analyses indicated that samples stored either at about 4° C. or about 37° C. for three days generated similar quantities of nucleic acid, ranging from 1 to 5 ng/μl, for all three specimens. Additionally, further analyses indicated that the same quantity of DNA was generated from samples stored 3 days at 4° C., 25° C., or 37° C. (FIG. 3). For example, nucleic acid profiles from hair stored in the inventive vessel at either 4° C. or 37° C. were indistinguishable (data not shown).
- Referring to FIGS. 6A-6F, nucleic acid profiles were generated using an AmpF/STR™ Profiler Plus PCR reaction kit that amplifies ten genetic loci for purposes of human identification. FIGS. 6A-6C are the ten genetic loci for nucleic acid profiles generated from blood samples according to the inventive method. FIGS. 6D-6F are the ten genetic loci for nucleic acid profiles generated from blood samples collected by conventional organic extraction methodology, as is known to one skilled in the art. The results between the methods are virtually indistinguishable.
- The container of the invention can be used for extraction and subsequent analysis of nucleic acid from either whole blood (either anticoagulated or coagulated), epithelial cells from the oral mucosa (buccal swabs), or hairs with intact roots. The nucleic acids extracted can be used to generate human profiles such as DNA profiles.
- The inventive vessel allows sample and storage for subsequent nucleic acid extraction and analysis in a unitary, self-contained system. Use of the vessel reduces hands-on time, which in turn reduces the risk of contamination, benefits long term storage, is amenable to different types of samples, and is cost effective.
- It should be understood that the embodiments of the present invention shown and described in the specification are only preferred embodiments of the inventor who is skilled in the art and are not limiting in any way. Therefore, various changes, modifications or alterations to these embodiments may be made or resorted to without departing from the spirit of the invention and the scope of the following claims.
Claims (23)
1. A method for temporally regulating nucleic acid analysis of a specimen comprising
providing said specimen to a vessel containing reagents for said nucleic acid analysis selectively segregated from said sample by at least one thermally breachable barrier, and
thereafter selectively breaching said barrier to regulate contact of said reagents with said specimen.
2. The method of claim 1 wherein said reagent is selected from the group consisting of lysing reagents, amplifying reagents, photosterilizing reagents, extracting reagents, detecting reagents and combinations thereof.
3. The method of claim 2 wherein said lysing reagent comprises a buffer, a detergent, a protease and combinations thereof.
4. The method of claim 2 wherein said photosterilizing reagent comprises a photoreagent, a chelator for magnesium ions, and combinations thereof.
5. The method of claim 2 wherein said amplifying reagent comprises a buffer, at least one nucleoside triphosphate, a magnesium containing compound, a polynucleotide polymerase, at least one oligonucleotide primer, and combinations thereof.
6. The method of claim 2 wherein said detecting reagent is selected from the group consisting of signal-generating substances and separation-promoting substances.
7. The method of claim 1 wherein said barrier is a hydrophobic substance.
8. The method of claim 1 wherein said barrier is a wax.
9. The method of claim 1 wherein said specimen is selected from the group consisting of blood, hair, and epithelial cells.
10. A method for temporally regulating extraction and digestion of nucleic acid in a sample comprising
providing said sample to a vessel containing reagents for said nucleic acid extraction selectively segregated from reagents for said nucleic acid digestion by a first thermally breachable barrier, said reagents also selectively segregated from said sample by a second thermally breachable barrier, and
thereafter selectively breaching said first and second barriers to regulate contact of said extraction and digestion reagents with said sample.
11. The method of claim 10 wherein said sample contacts said digestion reagent and thereafter contacts said extraction reagent.
12. The method of claim 10 wherein said sample contacts said digestion reagent and is stored in said vessel before contact with said extraction reagent.
13. An apparatus for temporally regulating analysis of nucleic acid in a specimen contained in said apparatus comprising a vessel containing one or more reagents for said analysis selectively segregated from said specimen by at least one thermally breachable barrier.
14. The apparatus of claim 13 wherein said barrier is comprised of a hydrophobic substance.
15. The apparatus of claim 14 wherein said hydrophobic substance comprises at least one wax.
16. The apparatus of claim 15 wherein said wax has a melting point of about 55° C.
17. The apparatus of claim 15 wherein the volume of wax is about 50 μl.
18. The apparatus of claim 13 capable of containing a maximum volume of about 500 μl.
19. The apparatus of claim 13 further comprising a closure.
20. A kit comprising
at least one apparatus for containing and temporally segregating a specimen from a reagent for analyzing a nucleic acid in said specimen, said apparatus comprising a vessel containing one or more reagents for said analysis and a thermally breachable barrier to selectively segregate said reagent from a sample added to said apparatus, and
instructions for breaching said barrier.
21. The kit of claim 20 further comprising at least one sample collection device.
22. The kit of claim 21 wherein said sample collection device is selected from the group consisting of a swab, a filter paper, and combinations thereof.
23. The kit of claim 21 further comprising a holder for said apparatus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/781,873 US6428962B1 (en) | 2001-02-12 | 2001-02-12 | Nucleic acid collection barrier method and apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/781,873 US6428962B1 (en) | 2001-02-12 | 2001-02-12 | Nucleic acid collection barrier method and apparatus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US6428962B1 US6428962B1 (en) | 2002-08-06 |
| US20020110812A1 true US20020110812A1 (en) | 2002-08-15 |
Family
ID=25124228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/781,873 Expired - Fee Related US6428962B1 (en) | 2001-02-12 | 2001-02-12 | Nucleic acid collection barrier method and apparatus |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US6428962B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745204B1 (en) | 2005-04-29 | 2010-06-29 | Georgia Tech Research Corporation | Automation of biological sample aliquoting |
| WO2011158037A2 (en) | 2010-06-18 | 2011-12-22 | Lgc Limited | Methods and apparatuses |
| WO2017106917A3 (en) * | 2015-12-22 | 2017-07-27 | Bio Molecular Systems Pty Ltd | Reaction container and cap assembly |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217513B2 (en) * | 2001-07-10 | 2007-05-15 | Massachusetts Institute Of Technology | Apparatus and method for isolating a nucleic acid from a sample |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| JP2005532072A (en) * | 2002-07-10 | 2005-10-27 | マサチューセッツ・インスティテュート・オブ・テクノロジー | Apparatus and method for isolating nucleic acids from a sample |
| US7947450B2 (en) | 2003-07-10 | 2011-05-24 | Universite Libre De Bruxelles | Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed |
| JP4472634B2 (en) * | 2003-07-10 | 2010-06-02 | ユニヴェルシテ リブル ドゥ ブリュッセル | Apparatus, kit and method for pulsing a biological sample with a reagent and thus stabilizing the pulsed sample |
| US7462475B2 (en) * | 2004-05-20 | 2008-12-09 | Dna Poleymerase Technology, Inc. | Use of whole blood in PCR reactions |
| ES2375379T3 (en) | 2005-12-09 | 2012-02-29 | Dna Genotek Inc. | CONTAINER SYSTEM TO STORE A SUBSTANCE SO THAT IT CAN BE RELEASED. |
| AU2012273121B2 (en) | 2011-06-19 | 2016-08-25 | Abogen, Inc. | Devices, solutions and methods for sample collection |
| CN105980558B (en) | 2013-12-12 | 2021-08-24 | 阿尔查技术有限公司 | Sample preparation method and apparatus |
| US10746683B2 (en) | 2013-12-12 | 2020-08-18 | Altratech Limited | Capacitive sensor and method of use |
| GB201417281D0 (en) * | 2014-09-30 | 2014-11-12 | Ge Healthcare Uk Ltd | Methods and devices relating to the detection of oral cancer biomarkers |
| NZ757589A (en) | 2017-03-15 | 2017-09-27 | Ancestry Com Dna Llc | Sample collection device and method |
| WO2019057515A1 (en) | 2017-09-20 | 2019-03-28 | Altratech Limited | Diagnostic device and system |
| WO2019070833A1 (en) | 2017-10-06 | 2019-04-11 | Ancestry.Com Dna, Llc | Systems, devices, and methods for sample collection |
| US11426734B2 (en) | 2017-11-22 | 2022-08-30 | Ancestry.Com Dna, Llc | Sample collection kit including cap having selectively movable sleeve |
| WO2019104215A1 (en) | 2017-11-22 | 2019-05-31 | Ancestry. Com Dna, Llc | Sample collection kit including cap having selectively movable sleeve |
| AU2020227306A1 (en) | 2019-02-27 | 2021-10-07 | Ancestry.Com Dna, Llc | Graphical user interface displaying relatedness based on shared DNA |
| CN120866034A (en) * | 2020-03-20 | 2025-10-31 | 厦门致善生物科技股份有限公司 | Device, kit and method for extracting nucleic acid |
| CN111286449B (en) * | 2020-04-01 | 2023-10-03 | 宁波艾捷康宁生物科技有限公司 | Biological sample pretreatment reagent integrated adding method and device |
| CN111939996B (en) * | 2020-10-19 | 2021-01-29 | 博奥生物集团有限公司 | In-test tube reagent storage method and reagent storage reaction detection integrated test tube |
| US12332902B2 (en) | 2022-04-20 | 2025-06-17 | Ancestry.Com Dna, Llc | Filtering individual datasets in a database |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4279863A (en) | 1979-09-12 | 1981-07-21 | Sherwood Medical Industries, Inc. | Reagent separator for a blood collection tube |
| US5362654A (en) | 1984-07-20 | 1994-11-08 | Sangstat Medical Corporation | Self-contained quantitative assay |
| US4889692A (en) | 1984-11-05 | 1989-12-26 | Holtzman Marc E | Disposable sample preparation container |
| US4690801A (en) | 1986-06-03 | 1987-09-01 | Allelix Inc. | Device for performing enzyme immunoassays |
| US4865813A (en) | 1986-07-07 | 1989-09-12 | Leon Luis P | Disposable analytical device |
| US5238649A (en) | 1988-02-09 | 1993-08-24 | Nason Frederic L | Specimen test unit |
| US5266266A (en) | 1988-02-09 | 1993-11-30 | Nason Frederic L | Specimen test unit |
| US5496562A (en) | 1988-10-05 | 1996-03-05 | Flinders Technologies Pty Ltd | Solid medium and method for DNA storage |
| US5152965A (en) | 1989-06-02 | 1992-10-06 | Abbott Laboratories | Two-piece reagent container assembly |
| US5103836A (en) | 1990-02-28 | 1992-04-14 | Epitope, Inc. | Oral collection device and kit for immunoassay |
| EP0515506B1 (en) | 1990-02-16 | 2000-01-05 | F. Hoffmann-La Roche Ag | Improvements in the specificity and convenience of the polymerase chain reaction |
| US5283038A (en) | 1990-12-18 | 1994-02-01 | Saliva Diagnostic Systems, Inc. | Fluid sampling and testing device |
| US5119830A (en) | 1991-04-03 | 1992-06-09 | Code Blue Medical Corporation | Analytical specimen cup with testing means |
| GB9114265D0 (en) | 1991-07-02 | 1991-08-21 | Amersham Int Plc | Sampling device |
| US5413924A (en) | 1992-02-13 | 1995-05-09 | Kosak; Kenneth M. | Preparation of wax beads containing a reagent for release by heating |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| EP0609431B1 (en) | 1992-08-24 | 1997-10-08 | Dade MicroScan Inc. | Sealable vessel for containing and processing analytical samples |
| US5565339A (en) * | 1992-10-08 | 1996-10-15 | Hoffmann-La Roche Inc. | Compositions and methods for inhibiting dimerization of primers during storage of polymerase chain reaction reagents |
| GB9223035D0 (en) | 1992-11-03 | 1992-12-16 | Kiessling Cooper Ann A | Preservation of peripheral blood & semen in fixatives that inactivate human pathogens |
| US5424040A (en) | 1992-11-09 | 1995-06-13 | Bjornsson; Bjorn L. | Tissue specimen collection kit |
| US5500339A (en) | 1993-03-30 | 1996-03-19 | Amersham Life Science, Inc. | DNA denaturation method |
| US5477863A (en) * | 1993-04-14 | 1995-12-26 | Grant; Michael A. | Collection kit with a sample collector |
| US5403551A (en) | 1993-09-16 | 1995-04-04 | Roche Diagnostic Systems, Inc. | Assaying device and container for in field analysis of a specimen and later shipment of the unadulterated specimen |
| AU8123594A (en) | 1993-10-22 | 1995-05-08 | Abbott Laboratories | Reaction tube and method of use to minimize contamination |
| US5576197A (en) | 1995-04-07 | 1996-11-19 | Molecular Bio-Products | Polymerase chain reaction container and methods of using the same |
| US5667985A (en) | 1996-09-24 | 1997-09-16 | Becton Dickinson And Company | Tissue biopsy cell suspender for cell analysis |
| US5714390A (en) | 1996-10-15 | 1998-02-03 | Bio-Tech Imaging, Inc. | Cartridge test system for the collection and testing of blood in a single step |
-
2001
- 2001-02-12 US US09/781,873 patent/US6428962B1/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745204B1 (en) | 2005-04-29 | 2010-06-29 | Georgia Tech Research Corporation | Automation of biological sample aliquoting |
| WO2011158037A2 (en) | 2010-06-18 | 2011-12-22 | Lgc Limited | Methods and apparatuses |
| US9139871B2 (en) | 2010-06-18 | 2015-09-22 | Lgc Limited | Methods and apparatuses |
| WO2017106917A3 (en) * | 2015-12-22 | 2017-07-27 | Bio Molecular Systems Pty Ltd | Reaction container and cap assembly |
Also Published As
| Publication number | Publication date |
|---|---|
| US6428962B1 (en) | 2002-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6428962B1 (en) | Nucleic acid collection barrier method and apparatus | |
| US11274291B2 (en) | Sample preparation method and apparatus | |
| DK2271767T3 (en) | Amplikonredning-multiplex polymerase chain reaction for the amplification of multiple target | |
| JP7723792B2 (en) | Methods for detecting silent carrier genotypes | |
| Paskewitz et al. | Use of the polymerase chain reaction to identify mosquito species of the Anopheles gambiae complex | |
| CN101203312B (en) | Cartridges, systems and methods for automated medical diagnosis | |
| JP5258835B2 (en) | Polynucleotide detection and quantification device | |
| EP1661988A1 (en) | Kit for nucleic acid detection | |
| JP2010536016A (en) | Sample processing equipment | |
| CN1950522A (en) | Method and device for amplifying DNA by means of PCR using dry reagents | |
| WO2011158037A2 (en) | Methods and apparatuses | |
| EP2426222A1 (en) | Generic buffer for amplification | |
| EP0530283B1 (en) | Method and means to perform biochemical reactions | |
| EP0572057A1 (en) | PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids | |
| CN101091113A (en) | Method of sample analysis and apparatus therefor | |
| JPH09238687A (en) | Nucleic acid synthesis method | |
| KR20180056343A (en) | Method for Simple and Highly Sensitive Molecular Diagnosis of Zika Virus Using Lateral Flow Assay Strip | |
| US5273907A (en) | Method and means for perform biochemical reactions | |
| US20080124716A1 (en) | Method and device for time-effective biomolecule detection | |
| WO2024238645A2 (en) | Penetrable gel in a reaction vessel | |
| KR101162422B1 (en) | Composition for amplifying nucleic acid | |
| AU2022270084B2 (en) | Systems, methods, and apparatus for automated self-contained biological analysis | |
| CN103382501A (en) | Positive control concept | |
| Decorte et al. | Genetic analysis of single hair shafts by automated sequence analysis of the mitochondrial d-loop region | |
| JPH1080279A (en) | Nucleic acid synthesis method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DNA ANALYSIS, INC., OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NAEGELE, BERNARD G.;REEL/FRAME:011545/0472 Effective date: 20010207 |
|
| CC | Certificate of correction | ||
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Expired due to failure to pay maintenance fee |
Effective date: 20140806 |